PROCANBID (procainamide hydrochloride) by Pfizer is clinical pharmacology procainamide (pa) increases the effective refractory period of the atria, and to a lesser extent the bundle of his-purkinje system and ventricles of the heart. Approved for documented ventricular arrhythmias, such, that and 1 more indications. First approved in 1996.
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
PROCANBID is a procainamide hydrochloride extended-release tablet, a Class 1A antiarrhythmic agent used to treat documented ventricular arrhythmias. It works by increasing the effective refractory period of cardiac tissue, reducing impulse conduction velocity, and decreasing myocardial excitability through inhibition of ectopic pacemaker activity. The drug is structurally similar to quinidine but has weaker vagal blocking action and less cardiac depression.
PROCANBID is approaching loss of exclusivity as a legacy antiarrhythmic with likely limited team size and focus on managed decline strategies.
CLINICAL PHARMACOLOGY Procainamide (PA) increases the effective refractory period of the atria, and to a lesser extent the bundle of His-Purkinje system and ventricles of the heart. It reduces impulse conduction velocity in the atria, His-Purkinje fibers, and ventricular muscle, but has variable…
Worked on PROCANBID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPROCANBID offers minimal career growth prospects given zero linked job openings and LOE-approaching lifecycle. Career value lies in legacy product management experience, market access negotiation, and managed decline strategy expertise rather than growth trajectory.